Eupatilin

Catalog No.S3846 Batch:S384602

Print

Technical Data

Formula

C18H16O7
Molecular Weight 344.32 CAS No. 22368-21-4
Solubility (25°C)* In vitro DMSO 69 mg/mL (200.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
3.45mg/ml Taking the 1 mL working solution as an example, add 50 μL of 69 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% corn oil
0.85mg/ml Taking the 1 mL working solution as an example, add 50 μL of 17 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Eupatilin (NSC 122413), a major flavonoid from Artemisia plants, possesses various beneficial biological effects including anti-inflammation, anti-tumor, anti-cancer, anti-allergy, and anti-oxidation activity. Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
In vitro Eupatilin has been reported to induce apoptosis in human gastric cancer AGS cells, also triggers differentiation of these cells. Treatment of AGS cells with eupatilin induces cell cycle arrest at the G1 phase with the concomitant induction of p21cip1, a cell cycle inhibitor. It also markedly induces trefoil factor1(TFF1). Eupatilin dramatically induces redistribution of tight junction proteins such as occludin and ZO-1, and F-actin at the junctional region between cells. It also induces phosphorylation of extracellular signal-regulated kinase 2 and p38 kinase. Eupatilin is known to inhibit the growth of MCF-10A-ras cells by inhibiting the expression of cell cycle regulators such as cyclinD1, cyclinB1, Cdk2, and Cdc2[1].
In vivo Treatment with eupatilin significantly decreases serum alanine aminotransferase and serum aspartate aminotransferase as well as liver histologic changes. Eupatilin also preventes hepatic glutathione depletion and increases malondialdehyde levels induced by Ischemia-reperfusion injury (IRI). It improves the acute hepatic IRI by reducing inflammation and apoptosis[2]. Oral administration of eupatilin (10 mg/kg) in a therapeutic paradigm significantly reduces brain infarction and improves neurological functions in tMCAO-challenged mice. Eupatilin administration reduces the number of Iba1-immunopositive cells across ischemic brain and induces their morphological changes from amoeboid into ramified in the ischemic core, which is accompanied with reduced microglial proliferation in ischemic brain. Eupatilin suppresses NF-κB signaling activities in ischemic brain by reducing IKKα/β phosphorylation, IκBα phosphorylation, and IκBα degradation[3].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    Human gastric epithelial AGS cells

  • Concentrations

    10-500 μM

  • Incubation Time

    24, 48, 72 h

  • Method

    Cellular viability is determined by PI incorporation. Cells are treated with various reagents, washed with PBS twice, resuspended in PBS containing 20 μg/ml PI, and then immediately analyzed on a FACSCalibur. PI-positive cells are counted as dead cells and the remaining cells are designated as viable cells.
Animal Study:[2]
  • Animal Models

    C57BL/6 mice

  • Dosages

    10 mg/kg

  • Administration

    oral

Selleck's Eupatilin has been cited by 4 publications

Eupatilin Ameliorates Hepatic Fibrosis and Hepatic Stellate Cell Activation by Suppressing β-catenin/PAI-1 Pathway [ Int J Mol Sci, 2023, 24(6)5933] PubMed: 36983006
Eupatilin attenuates the senescence of nucleus pulposus cells and mitigates intervertebral disc degeneration via inhibition of the MAPK/NF-κB signaling pathway [ Front Pharmacol, 2022, 13:940475] PubMed: 36408239
β-Caryophyllene Acts as a Ferroptosis Inhibitor to Ameliorate Experimental Colitis [ Int J Mol Sci, 2022, 23(24)16055] PubMed: 36555694
Eupatilin Treatment Inhibits Transforming Growth Factor Beta-Induced Endometrial Fibrosis in Vitro [ Clin Exp Reprod Med, 2020, 47(2):108-113] PubMed: 32460455

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.